BioCentury
ARTICLE | Emerging Company Profile

Alto: a computational, biomarker-based approach to neuropsychiatry

Stanford spinout uses algorithm to match previously studied treatments with patient populations

October 14, 2021 2:02 PM UTC

With $40 million in funding thus far, Stanford spinout Alto is developing psychiatric therapies for targeted populations using biomarkers it has identified by applying machine learning to ...



Access this Article

BCIQ Company Profiles

Alto Neuroscience Inc.